Making the difference.

Cholesterol is an essential lipid with multifaceted functions in human physiology (Figure 1). Panoxyvir research focuses on the actually existing link between cholesterol metabolism and innate/adapted immunity against viral infections.


Fig.1


The physiological metabolism of cholesterol is enzymatically mediated and leads to the production of oxidized metabolites, whose oxysterols are those mostly endowed with useful properties, provided that their concentration in the human body is maintained within a normal range.


Oxysterols are a family of 27-carbon molecules that, with respect to cholesterol, contain an additional hydroxy, epoxide or ketone group in the sterol nucleus and/or a hydroxyl group in the side chain (Figure 2).


Notably, there are other oxysterols that can be generated through non enzymatic reactions both in the cholesterol rich food during cooking or storage and in the body under pathophysiological conditions associated with random oxidation reactions (Figure 2).




Fig.2


The strong antiviral effect of some oxysterols is a quite recent disclosure and essentially limited to the sub-family of enzymatic origin.


The Panoxyvir founders discovered that the broad inhibitory antiviral activity exerted by 25-hydroxycholesterol (25HC) was not limited to enveloped viruses as first shown by Su-Yang Liu et al. (Immunity, 2013) and Blanc et al. (Immunity, 2013), but it was extended to non-enveloped ones. Moreover, at least another oxysterol of enzymatic origin, namely 27-hydroxycholesterol (25HC) appeared to be as effective as 25HC (Civra et al. Sci Rep, 2014) with a selectivity index even more favourable than this second oxysterol (Civra et al., unpublished).


Panoxyvir holds the patent for the antiviral activity of a number of oxysterols of natural origin against non-enveloped viruses, including Rhinovirus, Rotavirus and Papillomavirus.  The company’s research activity is primarily related to the the infections mediated by these three classes of viruses (Figure 3).


Nacked viruses studied



Fig.3


In particular, aside the preclinical development of the active substance (27HC) up to IND/IMPD filing, relevant intensive investigation is in progress with two major aims:


To elucidate in full the mechanism/s underlying the remarkably broad antiviral properties of 27HC and related oxysterols of enzymatic origin.

To provide further convincing evidence of a primary role of 27HC and related oxysterols in key physiological processes of innate and adaptive immunity as well as in cell and tissue health and function.

Contact us

Unique experiences to drive engagement


 
As experts in the antiviral field we offer our services to virtual start-up companies lacking the appropriate facilities to perform antiviral studies, and to large Biotechnology and Pharmaceutical companies seeking CROs with unique expertise in the virology field. Panoxyvir does not request ownership nor intellectual property rights over studies or compounds evaluated for other Life Sciences companies.


Antiviral services offered by Panoxyvir include a full menu of in vitro and ex vivo antiviral assays against several important human pathogens:


human herpes virus type 1 and 2

human cytomegalovirus

human adenovirus

human respiratory syncytial virus

human rhinovirus

human rotavirus

Zikavirus

human papillomavirus (pseudoviruses)

other viruses on request

Assays performed at Panoxyvir:


Plaque reduction assays

Virus yield reduction assays

Time of addition assays

Binding assays

Attachment/entry assays

Virus stability assessment (virucides and stabilizers)

In vitro drug-resistance virus selection

Ex vivo assays on reconstituted 3D respiratory, vaginal or intestinal human tissues

Customized virus production

Other assays on request

In vitro and/or ex vivo cytoxicity assays are available with all antiviral studies.


To request information or quotes contact us at info@panoxyvir.com


Learn more

12
Useful options
45
Beautiful snippets
8
Amazing pages
37
Outstanding images

Grow with Us

Put your people at the heart of your Panoxyvir main project is to develop the first drug to treat and prevent rhinovirus infections in patients with chronic inflammatory lung diseases.


We are seeking funding for the operation to develop our lead program (POV-2017) to be the first approved treatment for rhinovirus infections in cystic fibrosis patients. We are also looking for partners interested in co-development of oxysterol-based drugs to treat other diseases induced by non-enveloped viruses.


POV-2017: Rhinovirus infections in Cystic Fibrosis patients


POV-2017 is the lead compound currently in pre-clinical testing for first line treatment of Rhinovirus infections in pediatric and adult Cystic Fibrosis patients. The compound has a well-defined regulatory path that will take advantage of the orphan drug designation for Cystic Fibrosis, a rare disease. Completion of IND-IMPD enabling studies and files for an inhalation product is estimated to take about 2 years and cost approximately 2 mln euros.


POV-2017: Rhinovirus infections in other patients


POV-2017 can be developed to treat upper respiratory infections caused by Rhinovirus in asthmatic patients to prevent exacerbations and and in general population to cure the common cold.


Panoxyvir technology has the potential to address other viral diseases, including rotavirus infections (a major cause of pediatric gastroenteritis) and papillomavirus infections (genital and oral lesions)


Add a caption to enhance the meaning of this image.

Beginner

$ 35 .00

/ month
  • Basic sales & marketing for up to 2 users
  • Account & Sales management
  • No customization
  • No support

Professional

$ 65 .00

/ month
  • Complete CRM for any size team
  • Access to all modules
  • Limited customization
  • Email support

Expert

$ 125 .00

/ month
  • Unlimited CRM power and support
  • Access to all modules and features
  • Unlimited customization
  • 24/7 support